Cardiac monitor maker Kestra's Q2 revenue beats estimates

Reuters12-12
Cardiac monitor maker Kestra's <a href="https://laohu8.com/S/QTWO">Q2</a> revenue beats estimates

Overview

  • Wearable medical device firm's fiscal Q2 revenue rose 53%, beating analyst expectations

  • Adjusted EBITDA loss for fiscal Q2 beat analyst estimates

Outlook

  • Kestra increases FY26 revenue guidance to $91 mln, up from $88 mln

  • Company focuses on expanding commercial organization and wearable defibrillator market

Result Drivers

  • MARKET EXPANSION - Revenue growth driven by higher market share and WCD market expansion

  • GROSS MARGIN IMPROVEMENT - Gross margin expanded to 50.6% due to volume leverage and higher in-network patient mix

  • OPERATIONAL PROGRESS - Progress in commercial expansion and revenue cycle management supported results

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Revenue

Beat

$22.57 mln

$20.70 mln (6 Analysts)

Q2 EPS

-$0.64

Q2 Adjusted EBITDA

Beat

-$19.68 mln

-$20.56 mln (6 Analysts)

Q2 Gross Profit

$11.42 mln

Q2 Income from Operations

-$31.76 mln

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

  • Wall Street's median 12-month price target for Kestra Medical Technologies Ltd is $28.00, about 14.2% above its December 10 closing price of $24.52

Press Release: ID:nGNXbdHzb2

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment